TheraRadar
← Back
Data updated: Mar 29, 2026

THEA PHARMA

CardiovascularOphthalmologyInfectious Disease
Specialty

THEA PHARMA is a specialty pharmaceutical company focused on Cardiovascular, Ophthalmology, Infectious Disease. Key products include COSOPT PF.

1995
Since
8
Drugs
-
Trials
4
Approved (2yr)

Key Drugs

COSOPT PF
dorzolamide hydrochloride
Ophthalmology
Beta-1 adrenergic receptor 2 indications · 2012
ZOLYMBUS
bimatoprost
2 indications · 2025
IYUZEH
latanoprost
Ophthalmology
2 indications · 2022
ZIOPTAN
tafluprost
FP prostanoid receptor · 2012

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

AKTEN 2025-11-21
Labeling
ZOLYMBUS 2025-09-09
Type 3 - New Dosage Form
IYUZEH 2024-09-16
Labeling
AZASITE 2024-07-25
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 44%
4 drugs
Ophthalmology 44%
4 drugs
Infectious Disease 11%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Baxter specialty
Infectious Disease, Cardiovascular, Ophthalmology
B BRAUN specialty
Infectious Disease, Ophthalmology, Cardiovascular
BAUSCH AND LOMB specialty
Ophthalmology, Cardiovascular, Infectious Disease
FOUGERA PHARMS other
Ophthalmology, Infectious Disease, Cardiovascular
Novartis big-pharma
Cardiovascular, Ophthalmology